Ga-68 DOTA-NOC uptake in the pancreas: Pathological and physiological patterns

Clinical Nuclear Medicine

Volumn 37, Issue 1, 2012, Pages 57-62

  Krausz, Yodphat ^a   Rubinstein, Rina ^a   Appelbaum, Liat ^b   Mishani, Eyal ^a   Orevi, Marina ^a   Fraenkel, Merav ^b   Tshori, Sagi ^a   Glaser, Benjamin ^b   Bocher, Moshe ^a   Salmon, Asher ^a   Chisin, Roland ^a   Gross, David J ^b   Freedman, Nanette ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Ga 68 DOTA NOC; Neuroendocrine tumors; Pancreatic uptake; PET CT

Indexed keywords

DOTA 1 NAI3 OCTREOTIDE GA 68; GALLIUM 68; OCTREOTIDE; TETRAXETAN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DRUG UPTAKE; ENDOSCOPIC ECHOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; ORGANOMETALLIC COMPOUNDS; PANCREATIC NEOPLASMS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84856436096     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e3182393404     Document Type: Article

References (29)

1. Nissen NN, Kim AS, Yu R, et al. Pancreatic neuroendocrine tumors: presentation, management, and outcomes. Am Surg. 2009;75:1025-1029.
2. Franko J, Feng W, Yip L, et al. Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology, and outcomes in 2, 158 patients. J Gastrointest Surg. 2010;14:541-548.
3. Virgolini I, Traub-Weidinger T, Decristoforo C. Nuclear medicine in the detection and management of pancreatic islet-cell tumours. Best Pract Res Clin Endocrinol Metab. 2005;19:213-227. (Pubitemid 40347812)
4. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61-72.
5. Anderson MA, Carpenter S, Thompson NW, et al. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol. 2000;95:2271-2277.
6. Turner BG, Cizginer S, Agarwal D, et al. Diagnosis of pancreatic neoplasia with EUS and FNA: a report of accuracy. Gastrointest Endosc. 2010;71:91-98.
7. 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007;34:1617-1626. (Pubitemid 47476920)
8. 3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508-518. (Pubitemid 47571404)
9. 68Ga-DOTA-Tyr3- octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. J Nucl Med. 2009;50:1427-1434.
10. 68Ga-DOTATATE PET in neuroectodermal tumours: first experience. Nucl Med Commun. 2007;28:359-363. (Pubitemid 46569168)
11. Wild D, Schmitt JS, Ginj M, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging. 2003;30:1338-1347. (Pubitemid 37247950)
12. 68Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging. 2010;37:67-77.
13. 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nucl Med Commun. 2009;30:281-286.
14. 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging. 2008;35:1431-1438.
15. 68Ga-DOTA-NOC PET. Biomed Pharmacother. 2008;62:667-671.
16. ®). Mol Imaging Biol. 2011;13:583-593.
17. 68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2008;35:72-79. (Pubitemid 350234154)
18. 68Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. J Nucl Med. 2010;51:353-359.
19. Prasad V, Baum RP. Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions. Q J Nucl Med Mol Imaging. 2010;54:61-67.
20. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med. 2010;51:669-673.
21. 68Ga for medical application. J Nucl Med. 2007;48:1741-1748. (Pubitemid 47572722)
22. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-l8]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology. 1993;189:847-850. (Pubitemid 23354506)
23. 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37:2004-2010.
24. Wittingen J, Frey CF. Islet concentration in the head, body, tail and uncinate process of the pancreas. Ann Surg. 1974;179:412-414.
25. Portela-Gomes GM, Stridsberg M, Grimelius L, et al. Expression of the five different somatostatin receptor subtypes in endocrine cells of the pancreas. Appl Immunohistochem Mol Morphol. 2000;8:126-132. (Pubitemid 30609973)
26. Ballian N, Brunicardi FC, Wang XP. Somatostatin and its receptors in the development of the endocrine pancreas. Pancreas. 2006;33:1-12. (Pubitemid 43995333)
27. Strowski MZ, Blake AD. Function and expression of somatostatin receptors of the endocrine pancreas. Mol Cell Endocrinol. 2008;286:169-179.
28. Winter A, Bundschuh RA, Al-Ibraheem A, et al. Ga-68-DOTATOC PET/CT-potential pitfalls in the volume of the upper abdomen [abstract]. Eur J Nucl Med Mol Imaging. 2009;36(suppl 2):487S.
29. Al-Ibraheem A, Bundschuh R, Winter A, et al. Variable uptake patterns of 68Ga-DOTATOC in the head of the pancreas [abstract]. Eur J Nucl Med Mol Imaging. 2009;36(suppl 2): S202.